+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07064330

Using Next Generation Flow Cytometry to Identify Immune Profiles and Biomarkers for Response and Side Effects in Advanced Skin Cancer Patients Treated with Cemiplimab

Led by Instituto de Investigación Biomédica de Salamanca · Updated on 2025-09-10

30

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to identify biomarkers that predict how patients with advanced cutaneous squamous cell carcinoma CSCC respond to cemiplimab treatment and who might experience side effects. CSCC is a common skin cancer with a high rate of gene changes, especially affecting people with weakened immune systems. Cemiplimab is the first approved anti-PD1 therapy for this cancer, but about half of patients do not respond, and reasons for this are not well understood. The study uses advanced techniques like Next Generation Flow Cytometry to better understand immune responses and improve personalized treatment approaches. Participants with locally advanced or metastatic CSCC who are starting cemiplimab treatment as part of their usual care will be included. Blood and tumor samples will be collected and analyzed using specialized methods to profile immune cells and markers. The study begins with a small group to determine best sample times. Cemiplimab is given intravenously at 350 mg every three weeks, with patients monitored for immune response and possible side effects. During the study, researchers will track treatment outcomes including tumor response and immune-related side effects up to 12 months, with additional follow-up on survival and disease progression for up to two years. Blood and tumor tissue analyses will be performed at multiple points to correlate immune profiles with treatment effects. Safety and toxicity will be closely monitored throughout and after treatment, helping to inform future personalized therapies for CSCC patients.

CONDITIONS

Brief Title

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

Research Team

R

Ricardo López, Study Project Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here